

# COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers. Scientific brief

7 May 2020

## BACKGROUND

Concerns exist that angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) increase susceptibility to coronavirus SARS CoV-2 (the viral agent that causes the disease COVID-19) and the likelihood of severe COVID-19 illness<sup>(1)</sup>. These concerns are based on considerations of biological plausibility<sup>(2)</sup>, and the observation that there is an overrepresentation of patients with hypertension and other cardiovascular comorbidities among patients with COVID-19 who have poor outcomes<sup>(3)</sup>. Millions of people around the world are on treatment with ACE-Is and ARBs for hypertension, heart failure, coronary artery disease, or kidney disease. Speculation about worse outcomes among patients on these medications during the COVID-19 pandemic has caused widespread anxiety among patients and their care providers. On the other hand, the harms of indiscriminate withdrawal of these medications on cardiovascular outcomes are well documented<sup>(4)</sup>. There is also widespread speculation about the potential benefits of ACE-Is and ARBs, based on biological plausibility arguments and animal data and small clinical studies on patients with other viral respiratory infections<sup>(5)</sup>.

This brief summarizes the current evidence on the impact of ACE inhibitors or ARBs on severe acute respiratory illness due to SARS CoV-2.

## METHODS

A rapid review was carried out using Ovid MEDLINE and the Cochrane Database of Systematic Reviews from 1 January 2003 to 24 April 2020 as well as the World Health Organization database of COVID-19 publications, clinicaltrials.gov, and medRxiv.org from inception to 17 April 2020 using terms for COVID-19, SARS virus, Middle East respiratory syndrome, angiotensin-converting enzyme inhibitors, and angiotensin receptor antagonists. Additional citations were

identified from hand-searching reference lists. Studies in all languages were included. Study quality was assessed using the Newcastle-Ottawa Quality Assessment Scale.

## REVIEW OF THE EVIDENCE

The rapid review identified 11 observational studies<sup>(6–16)</sup>, eight of which were conducted in China<sup>(8–10,12–16)</sup>, along with single studies from Italy<sup>(11)</sup>, the United Kingdom<sup>(7)</sup>, and the United States<sup>(6)</sup>. Nearly all studies included only patients with lab-confirmed COVID-19. No studies were found that were designed to directly assess whether ACE inhibitors or ARBs increase the risk of acquiring COVID-19. After adjustment for confounders, history of ACE inhibitor or ARB use was not found to be associated with increased severity of COVID-19 illness. There were no studies that address the potential benefits and harms of initiating ACE inhibitors or ARBs as treatment for patients with COVID-19.

## CONCLUSION

There is low-certainty evidence that patients on long-term therapy with ACE inhibitors or ARBs are not at higher risk of poor outcomes from COVID-19.

## Piśmiennictwo

1. Watkins J: Preventing a covid-19 pandemic. *BMJ* 2020; 368: m810.
2. Wan Y, Shang J, Graham R et al.: Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. *J Virol* 2020; 94. pii: e00127-20.
3. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team: Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China, 2020. *China CDC Weekly* 2020; 2: 113–122.
4. Gilstrap LG, Fonarow GC, Desai AS et al.: Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. *J Am Heart Assoc* 2017; 6. pii: e004675.

5. Kuster GM, Pfister O, Burkard T et al.: SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? *Eur Heart J* 2020; 41: 1801–1803.
6. Rentsch CT, Kidwai-Khan F, Tate JP et al.: Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States veterans aged 54–75 years. *medRxiv* 2020. DOI: 10.1101/2020.04.09.20059964.
7. Bean D, Kraljevic Z, Searle T et al.: Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust. *medRxiv* 2020.
8. Liu Y, Huang F, Xu J et al.: Anti-hypertensive angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. *medRxiv* 2020. DOI: 10.1101/2020.03.20.20039586.
9. Feng Y, Ling Y, Bai T et al.: COVID-19 with different severity: a multi-center study of clinical features. *Am J Respir Crit Care Med* 2020. DOI: 10.1164/rccm.202002-0445OC.
10. Meng J, Xiao G, Zhang J et al.: Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg Microbes Infect* 2020; 9: 757–760.
11. Rossi GP, Marino M, Formisano D et al.: Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. *medRxiv* 2020. DOI: 10.1101/2020.04.13.20063545.
12. Yang G, Tan Z, Zhou L et al.: Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension. *medRxiv* 2020. DOI: 10.1101/2020.03.31.20038935.
13. Peng YD, Meng K, Guan HQ et al.: [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2020; 48: E004.
14. Zeng Z, Sha T, Zhang Y et al.: Hypertension in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study. *medRxiv* 2020. DOI: 10.1101/2020.04.06.20054825.
15. Li J, Wang X, Chen J et al.: Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. *JAMA Cardiol* 2020. DOI: 10.1001/jamacardio.2020.1624.
16. Zhang P, Zhu L, Cai J et al.: Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. *Circ Res* 2020. DOI: 10.1161/CIRCRESAHA.120.317134.